The GDF5 gene encodes growth differentiation factor 5¹¹ growth differentiation factor 5
a member of the bone morphogenetic protein (BMP) family essential for skeletal development, particularly in forming and maintaining cartilage in synovial joints. rs143383 is a C to T transition SNP located in the 5'untranslated region (5'UTR) of the GDF5 gene . This regulatory region controls how much GDF5 protein your cells produce, and the T allele of the SNP is associated with increased risk of osteoarthritis (OA) in Europeans and in Asians .

GDF5 is on the minus strand of chromosome 20, and this is an intron variant located in a critical regulatory region. While technically classified as an intron variant in some databases, it functions as a regulatory element in the gene's 5' UTR, affecting transcription.

The Mechanism

The A allele produces less GDF5 transcript relative to the G allele, a phenomenon known as differential allelic expression (DAE) . Studies show an average of 27% lower expression of the disease-associated A allele than the G allele in synovial joint tissues from OA patients . The mechanism involves transcription factor binding:

Sp1, Sp3, and DEAF-1 are repressors of GDF5 expression, with DEAF-1 modulating the differential allelic effect — the rs143383 A allele being repressed to a significantly greater extent than the G allele .

This reduced expression matters because GDF5 is essential for cartilage homeostasis. It promotes chondrocyte differentiation, stimulates production of cartilage matrix proteins like aggrecan and type II collagen²² cartilage matrix proteins like aggrecan and type II collagen
key structural components of healthy cartilage, and supports joint repair processes. Less GDF5 means less cartilage maintenance capacity over time.

The Evidence

GDF5 is the most compelling candidate association signal so far reported for OA, with the rs143383 single nucleotide polymorphism (SNP) showing association in both Europeans and Asians and at a significance level of P < 5.0 × 10⁻⁸ . The evidence spans multiple joint sites:

Knee osteoarthritis³³ Knee osteoarthritis
Valdes et al. (2011). The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance. Ann Rheum Dis.:

A significant random-effects summary OR for knee OA was demonstrated for rs143383 (1.15 [95% confidence interval 1.09-1.22]) (P=9.4×10⁻⁷), with no significant between-study heterogeneity . This is the strongest and most consistent association.

Lumbar disc degeneration⁴⁴ Lumbar disc degeneration
Williams et al. (2011). GDF5 single-nucleotide polymorphism rs143383 is associated with lumbar disc degeneration in Northern European women. Arthritis Rheum.:

An association between LDD and the SNP rs143383 was identified in women, with the same risk allele as in knee and hip OA (odds ratio 1.72 [95% confidence interval 1.15–2.57], P = 0.008) . The association was specific to women and particularly evident with severe disc degeneration.

Meta-analysis across musculoskeletal conditions⁵⁵ Meta-analysis across musculoskeletal conditions
Liu et al. (2018). Association between GDF5 rs143383 genetic polymorphism and musculoskeletal degenerative diseases susceptibility: a meta-analysis. BMC Med Genet.:

Meta-analysis of GDF5 rs143383 polymorphism was statistically associated with increased risk of musculoskeletal degenerative diseases under each genetic model (allele model: OR = 1.32, 95% CI 1.19–1.48, P = 0.000; homozygote model: OR = 1.80, 95%CI 1.49–2.16, P = 0.000) , covering 5,915 cases and 12,252 controls across both osteoarthritis and intervertebral disc degeneration.

The effect sizes are modest but highly reproducible — classic for common variants affecting complex traits. The A allele doesn't guarantee joint problems, but it tips the scales toward faster cartilage degradation over decades.

Practical Implications

This variant influences your joints' capacity to maintain and repair cartilage throughout life. The A allele creates a slight ongoing deficit in GDF5 expression, which compounds with age, mechanical stress, and other risk factors.

Weight matters more for you. With reduced cartilage maintenance capacity, excess mechanical load accelerates degeneration. Each extra 5 kg of body weight increases knee OA risk, and this effect is amplified when your baseline cartilage repair is compromised.

Joint-protective nutrients and supplements may help compensate. Glucosamine and chondroitin⁶⁶ Glucosamine and chondroitin
natural components of cartilage support cartilage structure. Studies show they can slow cartilage loss and reduce pain in OA, particularly the glucosamine sulfate form combined with chondroitin. Omega-3 fatty acids (EPA/DHA) reduce inflammatory responses in joints. Vitamin D and K support bone health underlying cartilage. SAM-e has shown cartilage-protective effects and pain relief comparable to NSAIDs.

Activity patterns should favor joint preservation. Low-impact exercise (swimming, cycling, elliptical) maintains joint health without excessive wear. Strength training builds muscle support around joints, offloading cartilage. Avoid chronic high-impact activities and repetitive joint stress if possible.

Interactions

This effect is influenced by a second SNP (rs143384, C/T) in the same area . The two variants work together to regulate GDF5 expression through methylation:

The G alleles of both SNPs form CpG dinucleotides. Demethylation of both SNP's increases GDF5 expression . When you carry the A allele at rs143383 along with the A allele at rs143384, the reduction in GDF5 expression is most pronounced. This represents a compound heterozygosity scenario where the combined genotype creates a stronger effect than either variant alone.

Other genes in cartilage homeostasis pathways may also interact with GDF5 function, including COL2A1 (type II collagen), ACAN (aggrecan), and other BMP family members, though specific compound implications require individual research into those variants.

The 9p21.3 region of chromosome 9 is one of the most functionally complex loci in the human genome. It encodes three tumor suppressors — p16INK4a, p14ARF (encoded by CDKN2A) and p15INK4b (encoded by CDKN2B)¹¹ p16INK4a, p14ARF (encoded by CDKN2A) and p15INK4b (encoded by CDKN2B)
These proteins are cyclin-dependent kinase inhibitors that halt cell-cycle progression and trigger senescence — and is also home to ANRIL (Antisense Non-coding RNA in the INK4 Locus)²² ANRIL (Antisense Non-coding RNA in the INK4 Locus)
Also designated CDKN2B-AS1 or CDKN2BAS — a long non-coding RNA transcribed on the antisense strand overlapping CDKN2A and CDKN2B, a molecular rheostat for how readily cells stop dividing and become senescent. rs1537377 is an independent endometriosis-risk signal at this locus, distinct from but in partial linkage disequilibrium with the index CDKN2BAS variants identified in Japanese GWAS.

The Mechanism

ANRIL regulates its neighboring tumor suppressors CDKN2A/B through epigenetic silencing. It recruits the PRC2 complex³³ PRC2 complex
Polycomb Repressive Complex 2 — a histone methyltransferase that adds H3K27me3 marks, compacting chromatin and silencing genes to deposit H3K27me3 on the CDKN2A/B promoters, and the PRC1 complex to maintain repression through histone H2A ubiquitination. The net effect is that ANRIL expression level determines how effectively cells keep their p15/p16 senescence checkpoint suppressed — allowing continued proliferation.

In endometriosis, this biology is directly relevant: ectopic endometrial cells implant at peritoneal and ovarian sites and must evade normal senescence and apoptosis to survive and proliferate in an ectopic environment. Functional fine-mapping at the 9p21.3 endometriosis locus showed that protective alleles drive stronger chromatin interaction with the ANRIL promoter⁴⁴ showed that protective alleles drive stronger chromatin interaction with the ANRIL promoter
Borghese et al. 2016 — Allelic Imbalance in Regulation of ANRIL through Chromatin Interaction at 9p21 Endometriosis Risk Locus. PLOS Genetics. via TCF7L2 and EP300 binding, increasing ANRIL transcription. More ANRIL means more CDKN2A/B silencing, which counterintuitively appears protective against endometriosis in this regulatory context, suggesting that the disease-associated haplotype disrupts normal ANRIL-mediated cell cycle regulation in endometrial stromal cells.

Consistent with this model, elevated ANRIL expression has been independently found in ectopic endometriotic tissue relative to normal ovarian epithelium with expression levels increasing progressively from ASRM stage II to stage IV⁵⁵ with expression levels increasing progressively from ASRM stage II to stage IV
Endometriosis Prognosis Correlates With Elevated Expression of LncRNA-ANRIL. Obstetrics & Gynecology International, 2025., suggesting that ANRIL dysregulation tracks disease severity rather than simply marking disease presence.

The Evidence

The first GWAS to implicate CDKN2BAS in endometriosis was conducted in 1,907 Japanese women with endometriosis and 5,292 controls⁶⁶ 1,907 Japanese women with endometriosis and 5,292 controls
Uno et al. 2010 — A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nature Genetics.. The lead SNP rs10965235 reached p=5.57×10⁻¹² (OR 1.44) and mapped to intron 16 of CDKN2BAS. rs1537377 represents a distinct signal at this locus identified in subsequent trans-ethnic meta-analysis.

In the Nyholt et al. (2012) GWAS meta-analysis of 4,604 cases and 9,393 controls⁷⁷ Nyholt et al. (2012) GWAS meta-analysis of 4,604 cases and 9,393 controls
Genome-wide association meta-analysis identifies new endometriosis risk loci. Nature Genetics. across Japanese and European samples, rs1537377 at 9p21.3 emerged as genome-wide significant in analyses restricted to moderate-to-severe European cases (OR approximately 1.15, p<5×10⁻⁸). The larger Rahmioglu et al. (2014) meta-analysis of 11,506 cases and 32,678 controls⁸⁸ Rahmioglu et al. (2014) meta-analysis of 11,506 cases and 32,678 controls
Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight GWAS and replication datasets. Human Reproduction Update. confirmed the association at p=1.5×10⁻⁸, and noted that eight of nine identified loci — including 9p21.3 — showed stronger effect sizes among Stage III/IV cases, consistent with a role in facilitating ectopic tissue invasion and persistence.

Belgian replication in 998 cases and 783 controls⁹⁹ in 998 cases and 783 controls
Sapkota et al. 2015 — Independent Replication and Meta-Analysis for Endometriosis Risk Loci. Twin Research and Human Genetics. confirmed rs1537377 among nine loci retaining genome-wide significance in European populations through meta-analysis, and noted that coding variants within CDKN2B-AS1 near rs1537377 also showed nominally significant associations.

Practical Actions

For women carrying one or two C alleles, the endometriosis risk signal at 9p21.3 is most actionable in two ways: earlier diagnostic vigilance for endometriosis (particularly moderate-to-severe presentations), and awareness that the 9p21.3 locus is shared with multiple other diseases including cardiovascular disease and several cancers, so any management of the locus's senescence pathway has broad implications.

The shared biology of 9p21.3 with ANRIL's role across diseases also means that interventions targeting cellular senescence — such as senolytic compounds that clear p16-positive cells — have theoretical relevance to the ectopic cell survival biology at this locus, though direct evidence in endometriosis specifically is not yet available.

Interactions

rs10965235 (CDKN2BAS): The index Japanese GWAS SNP at the 9p21.3 endometriosis locus. rs1537377 and rs10965235 tag the same chromosomal region but represent partially independent signals in trans-ethnic meta-analysis; combined carrier status would represent the full 9p21.3 endometriosis haplotype burden.

rs2811712 (CDKN2BAS): Another regulatory variant in ANRIL that primarily associates with physical aging and functional impairment through the same CDKN2B/p16 pathway. The two variants operate in the same ANRIL regulatory context but through different aspects of the locus.

rs1333049 (9p21.3 CAD locus): The primary coronary artery disease SNP at 9p21.3. Women with both the endometriosis-risk C allele at rs1537377 and the CAD-risk C allele at rs1333049 carry risk haplotypes at both faces of this pleiotropic locus, warranting combined cardiovascular and reproductive monitoring.

The IL1B gene encodes interleukin-1 beta (IL-1β), one of the most potent pro-inflammatory cytokines in the human body¹¹ one of the most potent pro-inflammatory cytokines in the human body
IL-1β drives inflammation, activates immune cells, and plays a central role in atherosclerosis, sepsis, and autoimmune disease. The rs16944 variant sits in the promoter region at position -511, where it functions as a genetic dimmer switch controlling how much IL-1β your cells produce²² where it functions as a genetic dimmer switch controlling how much IL-1β your cells produce
The A allele is associated with higher IL-1β mRNA expression, while the G allele produces less.

This isn't just an academic curiosity — rs16944 influences your risk of sepsis, cardiovascular disease mortality, and inflammatory complications across dozens of conditions³³ rs16944 influences your risk of sepsis, cardiovascular disease mortality, and inflammatory complications across dozens of conditions
From aspirin-induced asthma to coronary artery lesions in children, this variant shapes inflammatory outcomes.

The Mechanism

The -511 position in the IL1B promoter contains a binding site for transcription factors that regulate gene expression⁴⁴ contains a binding site for transcription factors that regulate gene expression
The C-to-T change (G-to-A on the forward strand) alters the binding affinity of these regulatory proteins. The A allele creates a promoter configuration that permits higher transcription rates⁵⁵ The A allele creates a promoter configuration that permits higher transcription rates
This results in elevated IL-1β mRNA and protein levels after immune stimulation.

IL-1β itself drives a cascade of inflammatory responses: it induces other cytokines like IL-6, activates endothelial cells to express adhesion molecules, promotes prostaglandin synthesis, and recruits immune cells to sites of inflammation⁶⁶ drives a cascade of inflammatory responses: it induces other cytokines like IL-6, activates endothelial cells to express adhesion molecules, promotes prostaglandin synthesis, and recruits immune cells to sites of inflammation
This amplification loop means a small genetic change in IL-1β production gets magnified throughout the immune system.

Critically, IL-1β is the key output of the NLRP3 inflammasome⁷⁷ IL-1β is the key output of the NLRP3 inflammasome
When danger signals like cholesterol crystals, uric acid, or pathogens activate this molecular complex, IL-1β is cleaved from its inactive precursor and released. Your rs16944 genotype determines how much raw material is available for this process.

The Evidence

The clearest evidence comes from sepsis studies. In 471 preterm infants, the AA genotype was significantly more common in those with early-onset sepsis (p=0.012) and was even more strongly associated with lethal outcomes (p=0.011)⁸⁸ In 471 preterm infants, the AA genotype was significantly more common in those with early-onset sepsis (p=0.012) and was even more strongly associated with lethal outcomes (p=0.011). In adult sepsis, AA carriers showed higher mortality risk⁹⁹ In adult sepsis, AA carriers showed higher mortality risk.

For cardiovascular disease, a 15-year follow-up of 2,010 Northern Ireland men found the A allele associated with increased all-cause mortality (HR 1.18, p=0.005)¹⁰¹⁰ a 15-year follow-up of 2,010 Northern Ireland men found the A allele associated with increased all-cause mortality (HR 1.18, p=0.005). The effect was dose-dependent: one A copy increased risk 18%, two copies increased it 43%¹¹¹¹ The effect was dose-dependent: one A copy increased risk 18%, two copies increased it 43%. This aligns with extensive evidence that IL-1β drives atherosclerosis progression¹²¹² extensive evidence that IL-1β drives atherosclerosis progression
The CANTOS trial demonstrated that blocking IL-1β with canakinumab reduces cardiovascular events in high-risk patients.

In more specific inflammatory conditions, AA homozygotes show 2.98-fold increased risk of aspirin-exacerbated respiratory disease¹³¹³ AA homozygotes show 2.98-fold increased risk of aspirin-exacerbated respiratory disease, and in children under 12 months with Kawasaki disease, GG carriers (lower IL-1β producers) had significantly reduced risk of coronary artery lesions¹⁴¹⁴ in children under 12 months with Kawasaki disease, GG carriers (lower IL-1β producers) had significantly reduced risk of coronary artery lesions.

A meta-analysis found the variant associated with silent myocardial ischemia in diabetic patients¹⁵¹⁵ A meta-analysis found the variant associated with silent myocardial ischemia in diabetic patients
Under multiple inheritance models, the CC/CT genotypes (corresponding to AA/AG in forward orientation) increased risk with OR of 4.68 for homozygotes.

Practical Implications

If you carry one or two A alleles, you have a genetic predisposition to mount stronger IL-1β responses. This is a double-edged sword: potentially more effective at clearing infections initially, but prone to excessive inflammation that damages your own tissues¹⁶¹⁶ prone to excessive inflammation that damages your own tissues
Chronic low-grade inflammation accelerates atherosclerosis, increases thrombosis risk, and contributes to age-related disease.

The cardiovascular connection is particularly important. IL-1β induces IL-6 production, which drives hepatic synthesis of fibrinogen, plasminogen activator inhibitor, and C-reactive protein¹⁷¹⁷ IL-1β induces IL-6 production, which drives hepatic synthesis of fibrinogen, plasminogen activator inhibitor, and C-reactive protein
This shifts hemostasis toward a prothrombotic state while creating an inflammatory milieu that destabilizes atherosclerotic plaques. If you're AA and have existing cardiovascular risk factors, you're in a higher-risk category for events.

The sepsis association matters for surgical planning and critical illness. AA carriers may benefit from more aggressive infection monitoring and earlier intervention when signs of systemic inflammation appear.

Interactions

This variant sits within a tightly linked haplotype block with rs1143627 (-31C>T), another functional IL1B promoter SNP¹⁸¹⁸ tightly linked haplotype block with rs1143627 (-31C>T), another functional IL1B promoter SNP
The two variants are in nearly complete linkage disequilibrium, meaning they're usually inherited together. When evaluating IL-1β-related risk, consider both variants as a unit.

The IL-1 gene cluster on chromosome 2q13 also includes IL1A and IL1RN (encoding the IL-1 receptor antagonist). Variants in IL1RN can modulate the overall balance between pro- and anti-inflammatory signaling¹⁹¹⁹ Variants in IL1RN can modulate the overall balance between pro- and anti-inflammatory signaling
High IL-1Ra production may partially buffer the effects of high IL-1β.

From a pathway perspective, IL-1β functions upstream of many inflammatory cascades. Variants in downstream genes like IL6, TNF, and CRP may compound or mitigate the effects of rs16944 on disease risk.

The CHRNA5 gene encodes the alpha-5 subunit of the nicotinic acetylcholine receptor (nAChR), a critical component of the brain's response to nicotine. The rs16969968 variant¹¹ The rs16969968 variant
This SNP is one of the most replicated genetic findings in addiction research, identified independently by multiple genome-wide association studies replaces aspartic acid with asparagine at position 398 of the alpha-5 subunit, fundamentally altering how your brain responds to nicotine. This single amino acid change has emerged as the strongest known genetic risk factor for heavy smoking and nicotine dependence.

The variant sits in the CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15q25, a region that has been consistently associated with smoking quantity²² consistently associated with smoking quantity
Meta-analyses report p-values as low as 5.57×10⁻⁷², making this one of the most significant genetic associations with any behavior across populations of European, Asian, African, and Latino ancestry. About 28% of Europeans carry at least one copy of the risk allele, though this frequency varies dramatically by population—only 2% of East Asians carry the A allele, while 15% of South Asians and Latinos do.

The Mechanism

The Asp398Asn substitution alters the structure of the alpha-5 subunit in a critical region called the second intracellular loop, which is highly conserved across species³³ highly conserved across species
The aspartic acid at position 398 is preserved in mammals, suggesting strong evolutionary pressure to maintain this amino acid. When incorporated into α4β2α5 nicotinic receptors, the 398N (risk) variant reduces receptor function by approximately 50%⁴⁴ reduces receptor function by approximately 50%
In vitro studies show the risk allele produces twofold lower maximal response to nicotinic agonists compared to the protective allele, measured by calcium influx and electrophysiological responses.

These α4β2α5 receptors are particularly abundant in the medial habenula and interpeduncular nucleus⁵⁵ medial habenula and interpeduncular nucleus
These brain regions form a critical pathway that normally limits nicotine intake by generating aversive responses to high nicotine doses, structures that act as a natural brake on nicotine consumption. The reduced receptor function in risk allele carriers weakens this braking system. Behavioral studies confirm this: individuals with the AA genotype report significantly lower aversive effects from nicotine⁶⁶ individuals with the AA genotype report significantly lower aversive effects from nicotine
In controlled intravenous nicotine administration, AA carriers rated nicotine as less unpleasant (P<5×10⁻⁸), with the effect most pronounced at higher doses, meaning they experience less nausea, dizziness, and discomfort that would normally discourage heavy smoking.

The Evidence

Multiple genome-wide association studies⁷⁷ genome-wide association studies
The initial 2008 GWAS from three independent research groups all converged on the same chromosomal region identified rs16969968 as the most significant variant associated with smoking quantity. A 2010 meta-analysis pooling data from European populations⁸⁸ meta-analysis pooling data from European populations
Analyzing over 140,000 individuals found rs16969968 with p=5.57×10⁻⁷² for cigarettes per day found that each A allele increases smoking quantity by approximately 1 cigarette per day, with an odds ratio of 1.3 for being a heavy smoker (≥20 cigarettes/day) versus a light smoker (≤10 cigarettes/day).

The effect extends across multiple populations⁹⁹ multiple populations
A cross-ancestry meta-analysis found consistent OR=1.33 across European, Asian, and African populations, though effect sizes vary, though with varying effect sizes. In European Americans, each A allele confers OR=1.3 for nicotine dependence. In African Americans, where the allele is rarer (6% frequency), the effect is similar (OR=1.3) when present. Studies in Mexican populations¹⁰¹⁰ Mexican populations
Mexican cohort showed OR=3.12 for heavy smoking in AA carriers versus GG and Middle Eastern populations¹¹¹¹ Middle Eastern populations
Palestinian lung cancer cases showed 36.7% A allele frequency versus 17.5% in controls report even stronger associations, though these may reflect population-specific factors.

The variant also affects smoking cessation outcomes¹²¹² smoking cessation outcomes
Meta-analyses show AA carriers have delayed time to cessation and lower success rates across multiple cessation interventions. Individuals with the AA genotype quit smoking later in life and have lower success rates with standard cessation interventions. One meta-analysis found the AA genotype is associated with a 7-year earlier lung cancer diagnosis¹³¹³ 7-year earlier lung cancer diagnosis
Among lung cancer patients, AA carriers were diagnosed 7 years earlier on average (HR=0.68, p=4.9×10⁻¹⁰) in smokers who do develop lung cancer.

Beyond nicotine dependence, the variant shows a dose-dependent association with lung cancer risk¹⁴¹⁴ a dose-dependent association with lung cancer risk
Each A allele increases lung cancer risk with OR=1.3-1.6, even after adjusting for smoking quantity, with odds ratios ranging from 1.3 to 1.6 per risk allele in different studies. This association persists even after adjusting for smoking quantity, suggesting both a behavioral pathway (more smoking) and potentially a direct biological effect. The variant has also been linked to chronic obstructive pulmonary disease (COPD)¹⁵¹⁵ chronic obstructive pulmonary disease (COPD)
Mexican cohort showed OR=1.91 for COPD in A allele carriers, another smoking-related disease.

Interestingly, the same allele that increases nicotine dependence appears to be protective against cocaine dependence¹⁶¹⁶ protective against cocaine dependence
In two independent samples, the A allele showed OR=0.67 for cocaine dependence—the opposite direction from nicotine, with odds ratios in the opposite direction (OR=0.67). This paradox suggests the variant's effects are specific to nicotine rather than reflecting general addiction vulnerability.

Practical Implications

If you carry one or two copies of the A allele, understand that your brain's natural aversion to nicotine is blunted. You're genetically predisposed to find smoking less unpleasant than others, making it easier to escalate to heavy smoking and harder to quit. This is not a character flaw—it's neurobiology.

For smoking prevention, awareness matters most before starting. If you've never smoked and carry the AA genotype, you face approximately 4-fold increased risk¹⁷¹⁷ approximately 4-fold increased risk
Studies report ORs ranging from 1.9 for heterozygotes to 3.6 for AA homozygotes for developing nicotine dependence of developing severe nicotine dependence if you do start, compared to GG carriers. Even "social smoking" may escalate more quickly.

For current smokers with the risk genotype, cessation requires more intensive support. Standard approaches like nicotine replacement therapy¹⁸¹⁸ nicotine replacement therapy
Some evidence suggests NRT efficacy varies by genotype, though this remains under investigation and behavioral counseling may be insufficient. Evidence suggests varenicline (Chantix)¹⁹¹⁹ varenicline (Chantix)
Varenicline acts on α4β2 nAChRs and appears effective regardless of CHRNA5 genotype may be particularly effective for risk allele carriers because it works regardless of your CHRNA5 genotype, unlike some cessation aids whose efficacy varies by genetic background.

The lung cancer risk deserves serious attention. Even among smokers, those with the AA genotype develop lung cancer earlier²⁰²⁰ those with the AA genotype develop lung cancer earlier
Meta-analysis of 12,690 smokers found AA carriers diagnosed 7 years earlier on average and at younger ages. However, the same study found that quitting smoking reduces lung cancer risk equally²¹²¹ quitting smoking reduces lung cancer risk equally
Smoking cessation showed OR=0.48 for lung cancer across all genotypes across all genotypes—the protective effect of quitting does not depend on your CHRNA5 status. Quitting smoking cuts your lung cancer risk in half regardless of your genetic background.

Interactions

The CHRNA5 rs16969968 variant is in strong linkage disequilibrium with rs1051730 in the CHRNA3 gene (r²=1 in Europeans), meaning they are almost always inherited together and their effects are difficult to separate. The 15q25 region also contains CHRNB4 and several other variants (rs588765, rs578776, rs6495309) that show associations with smoking behaviors, though rs16969968 appears to be the primary functional variant based on in vitro studies and cross-population analyses.

The variant's effect on smoking behavior is modified by age of smoking initiation²²²² modified by age of smoking initiation
Meta-analysis found the genetic effect is strongest in those who started smoking before age 16, with stronger genetic effects in those who start smoking during adolescence. Environmental factors like childhood adversity and peer smoking also interact with the genotype to influence dependence risk, though the specific mechanisms remain under investigation.

While rs16969968 is the strongest single genetic predictor of nicotine dependence, it explains only a small fraction of overall addiction risk. Smoking behavior is highly polygenic, with dozens of additional variants across the genome contributing smaller effects. Your genotype at this SNP should inform risk assessment and treatment planning, but it does not determine your destiny.

Your body's ability to build long-chain omega-3 and omega-6 fatty acids from dietary precursors hinges on a single enzyme: delta-5 desaturase¹¹ delta-5 desaturase
FADS1 (Fatty Acid Desaturase 1) — the enzyme that adds a double bond at the fifth carbon position, converting DGLA to arachidonic acid in the omega-6 pathway and eicosatetraenoic acid (ETA) to EPA in the omega-3 pathway. rs174541 is an intronic variant in the FADS gene cluster on chromosome 11q12.2 that acts as an independent regulator of how much FADS1 enzyme your cells make. The C allele dampens FADS1 expression, reducing the throughput of both the omega-6 pathway (less arachidonic acid from dietary linoleic acid) and the omega-3 pathway (less EPA from plant-derived ALA). Because the C allele also affects circulating triglyceride concentrations, this variant sits at the junction between fatty acid metabolism and broader cardiometabolic risk.

The Mechanism

rs174541 sits within FADS1's intronic regulatory architecture, in high linkage disequilibrium with the established functional cluster of FADS1 variants (rs174546, rs174547, rs174548, rs174537). Intronic variants in this region influence transcription factor binding sites and enhancer elements between FADS1 and FADS2 — the C allele at rs174541 tracks with reduced FADS1 mRNA levels and lower delta-5 desaturase enzyme activity across liver and blood cells.

The functional consequence plays out across two metabolic pathways simultaneously. In the omega-6 pathway: dietary linoleic acid (LA) → GLA → DGLA → [delta-5 desaturase] → arachidonic acid (AA). Reduced FADS1 activity means more DGLA accumulates and less AA is produced. In the omega-3 pathway: plant ALA → stearidonic acid → ETA → [delta-5 desaturase] → EPA. Again, the rate-limiting step is impaired, meaning less EPA is synthesised from the plant-sourced precursor. Neither pathway can compensate for the other — both require the same enzyme.

The Evidence

A Bayesian quantitative trait nucleotide analysis²² Bayesian quantitative trait nucleotide analysis
Voruganti et al. Variants in CPT1A, FADS1, and FADS2 are Associated with Higher Levels of Estimated Plasma and Erythrocyte Delta-5 Desaturases in Alaskan Eskimos. Front Genet, 2012 in 761 Alaskan Eskimos assigned rs174541 a posterior probability >0.8 for functional effect on erythrocyte delta-5 desaturase activity — the strongest statistical evidence available in a Bayesian framework for a variant being causally linked to its phenotype, not merely in LD with the causal site.

The broader FADS1 locus evidence is overwhelming. A landmark GWAS in the InCHIANTI study³³ landmark GWAS in the InCHIANTI study
Tanaka et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 of 1,075 Italian adults found that FADS1 cluster variants explain 18.6% of all additive variance in circulating arachidonic acid (p=5.95×10⁻⁴⁶), by far the largest explained variance for any common PUFA-metabolism variant. The CHARGE Consortium meta-analysis⁴⁴ CHARGE Consortium meta-analysis
Lemaitre et al. Genetic loci associated with plasma phospholipid n-3 fatty acids. PLoS Genet, 2011 across 8,866 European ancestry participants confirmed that FADS1 minor alleles are the dominant genetic predictor of lower circulating EPA (p=5×10⁻⁵⁸) and higher plant ALA (p=3×10⁻⁶⁴).

Beyond fatty acid ratios, FADS1 variants have direct consequences for clinical lipid panels. In 21,004 Japanese individuals⁵⁵ 21,004 Japanese individuals
Nakayama et al. A single nucleotide polymorphism in the FADS1/FADS2 gene is associated with plasma lipid profiles. Hum Genet, 2010, the C allele at the tightly linked rs174547 was significantly associated with higher triglycerides (p=1.5×10⁻⁶) and lower HDL-C (p=0.03), demonstrating that FADS1 reduced activity has effects visible on a standard fasting lipid panel — not just on specialised PUFA measurements. A study of 8,842 Korean adults⁶⁶ study of 8,842 Korean adults
Lee et al. Functional Impact of the FADS1 rs174546 Single Nucleotide Polymorphism on Serum Lipid Levels. Mol Nutr Food Res, 2024 quantified this: the FADS1 minor allele increases fasting serum triglycerides by 6.48 ± 1.84 mg/dL per allele, mediated through reduced LC-PUFA production and downstream effects on VLDL assembly and clearance.

Practical Actions

For C allele carriers, the core problem is that dietary plant-based omega-3 sources (flaxseed, chia, walnuts, canola oil) supply ALA which requires FADS1 to reach EPA. When FADS1 activity is reduced, that conversion chain slows — the ALA enters the bloodstream but stalls before reaching EPA. Direct supplementation with preformed EPA and DHA from marine or algae-based sources entirely bypasses the impaired step. The dosage depends on genotype: CT carriers benefit from 1–2 g EPA+DHA daily; CC homozygotes need 2–4 g to overcome the more complete impairment.

The triglyceride finding adds a monitoring dimension. If you carry the C allele and have other cardiovascular risk factors, a fasting lipid panel captures the clinical footprint of this genotype — elevated triglycerides and reduced HDL are the measurable downstream signal of impaired FADS1 activity.

Interactions

rs174541 is in high linkage disequilibrium (r² >0.8) with the established FADS1 functional cluster including rs174547, rs174548, rs174546, and rs174537. Users may carry risk alleles at multiple sites on the same haplotype — carrying the C allele at rs174541 in combination with risk alleles at rs174548 and rs174547 increases the probability of being on the full reduced-function FADS1 haplotype. No additional effect beyond what each individual variant predicts is needed for interpretation, as the variants tag the same underlying expression phenotype.

The ELOVL2 gene variant rs17606561 (also in the platform) encodes elongase 2, which converts EPA to DHA. A user who carries both FADS1 reduced-activity alleles and an ELOVL2 impairment faces a double block in the ALA → EPA → DHA pathway, potentially producing the most severe DHA deficiency of any single-enzyme genotype combination. For such users, a DHA-specific supplement target (≥500 mg DHA per day) matters beyond total EPA+DHA.

Beneath the surface of every coronary artery, a biochemical signaling system continuously directs immune cells to sites of injury and repair. At the center of this system is CXCL12¹¹ CXCL12
C-X-C motif chemokine ligand 12, also known as stromal cell-derived factor 1 (SDF-1), a chemokine that acts as a powerful attractant for progenitor cells, natural killer cells, and immune progenitors via its receptor CXCR4. The rs1746048 variant lies approximately 80 kilobases downstream of the CXCL12 gene on chromosome 10q11.21 and is one of the earliest and most consistently replicated genome-wide significant loci for coronary artery disease (CAD). It was among the first loci to reach genome-wide significance in large GWAS meta-analyses and has been replicated across European, East Asian, and South Asian populations.

The Mechanism

The rs1746048 variant does not alter the CXCL12 protein directly. It is an intergenic regulatory variant that modulates how much CXCL12 protein circulates in the bloodstream. Carriers of the risk C allele have demonstrably higher plasma CXCL12 levels than T allele carriers. Mehta et al. (2011)²² Mehta et al. (2011)
The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels, Eur Heart J 2011 showed a dose-dependent relationship: CC carriers had the highest CXCL12 levels, CT intermediate, and TT the lowest (2.33 vs 2.27 vs 2.21 ng/mL, P=0.034), and identified elevated CXCL12 transcript expression in natural killer cells and liver tissue as the downstream effectors.

Elevated CXCL12 promotes atherosclerosis through several mechanisms: it accelerates the migration and retention of hematopoietic progenitor cells³³ hematopoietic progenitor cells
bone marrow-derived precursor cells including monocyte precursors into arterial walls, increases the homing of inflammatory immune cells to developing plaques, and drives neovascularization⁴⁴ neovascularization
formation of new blood vessels within plaques, which are structurally fragile and prone to hemorrhage of atherosclerotic lesions. Additionally, a 2017 Pakistani study found that the C risk allele is associated with elevated IL-18 and a higher IL-18:IL-10 pro-inflammatory ratio, pointing toward dysregulated cytokine balance as a downstream consequence of elevated CXCL12 signaling.

The variant's effect on carotid intima-media thickness — a direct measure of subclinical atherosclerosis — has been quantified. A 2015 meta-analysis found that each C allele is associated with approximately 0.008 mm thicker carotid walls, suggesting the variant promotes vascular remodeling independent of established lipid risk factors.

The Evidence

The evidence base for rs1746048 is substantial and unusually consistent across ethnic groups. The most comprehensive meta-analysis, Chen et al. (2017)⁵⁵ Chen et al. (2017)
Meta-analysis pooling 48,852 CHD patients and 64,386 controls from 12 studies, Medicine (Baltimore), found per-C-allele odds ratios of 1.07 in Asian populations and 1.14 in Caucasian populations (1.11 overall). A concurrent meta-analysis by Huang et al. (2013)⁶⁶ Huang et al. (2013)
Case-control study in Han Chinese plus meta-analysis of >107,000 individuals, Gene confirmed an OR of 1.12 (P<0.0001), with subgroup analysis showing the effect is amplified in older patients (OR 1.91 for age ≥65) and males under a recessive model (OR 1.72 for CC+CT vs TT).

The longitudinal evidence is equally convincing. Wirtwein et al. (2017)⁷⁷ Wirtwein et al. (2017)
1,345 confirmed CAD patients with 8.6-year follow-up, Int J Cardiol showed that rs1746048 predicted both the need for revascularization procedures and major adverse cardiovascular events (MACE), indicating that the variant does not merely associate with incident CAD but also with its clinical severity and progression over time.

Practical Actions

The rs1746048 C allele is common — approximately 68% of people globally carry CC. Its per-allele effect is modest (OR ~1.12 per C allele), but it is one of the more robustly replicated GWAS hits for CAD, and its effect through elevated CXCL12 levels means it operates through an inflammatory pathway distinct from the standard lipid-driven mechanisms targeted by statins.

The T allele is protective and dose-dependent: CT carriers have measurably lower plasma CXCL12 levels and modestly lower CAD risk than CC carriers, and TT homozygotes have the lowest CXCL12 levels of all. For CC homozygotes, the key clinical implication is earlier subclinical atherosclerosis screening — particularly carotid intima-media thickness measurement and coronary artery calcium scoring — since the mechanistic evidence points directly to arterial wall thickening as a downstream effect.

Interactions

The strongest documented interaction is with rs501120, a neighboring variant also on chromosome 10q11.21 and also downstream of CXCL12. Mehta et al. showed that rs1746048 and rs501120 are both independently associated with CAD risk and both regulate plasma CXCL12 levels, suggesting that the 10q11.21 locus contains multiple functional regulatory elements rather than a single causal variant. Combined genotype data for these two SNPs has not been formally analyzed in a compound heterozygosity framework.

rs1746048 also co-occurs in multi-locus CAD genetic risk scores alongside rs4977574 (CDKN2B-AS1 / 9p21 locus) and rs1333049 (another 9p21 variant). The 9p21 locus and the 10q11.21 locus operate through distinct mechanisms — cell cycle regulation versus chemokine-driven inflammation respectively — meaning that carrying risk alleles at both loci compounds risk through non-overlapping biological pathways.

Your nervous system uses adrenaline as a metabolic switch — flooding tissues with it during stress to mobilize energy. In two critical tissues, this signal travels through the alpha-2A adrenergic receptor¹¹ alpha-2A adrenergic receptor
A G-protein-coupled receptor that mediates inhibitory responses to adrenaline and noradrenaline: pancreatic beta cells, where it suppresses insulin secretion, and fat cells, where it applies the brakes on lipolysis (fat breakdown). A variant 1,291 base pairs upstream of the ADRA2A gene (-1291C>G) alters how much of this receptor protein a cell makes — and that difference has measurable consequences for how your body handles metabolic stress and responds to certain medications.

The Mechanism

The ADRA2A gene encodes the alpha-2A adrenergic receptor, which is expressed at high levels in pancreatic beta cells and adipocytes. When adrenaline activates this receptor, it inhibits cAMP production, suppressing both glucose-stimulated insulin secretion and incretin-amplified insulin release via the cAMP/TRPM2 signalling axis²² cAMP/TRPM2 signalling axis
Transient receptor potential melastatin 2 channels couple alpha-2A receptor activation to reduced membrane excitability in beta cells. In adipose tissue, the same inhibitory signal reduces lipolytic flux, favouring fat retention.

The -1291 position lies in the promoter region — the DNA segment that governs how much RNA (and ultimately protein) the gene produces. Small et al. 2006³³ Small et al. 2006
Small KM et al. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. PNAS, 2006 demonstrated that noncoding haplotypes across the ADRA2A gene produce up to 5-fold differences in receptor transcript and surface protein levels across cell lines. Higher receptor density means a stronger adrenergic brake on insulin secretion and a tighter hold on stored fat.

The Evidence

The clearest clinical signal for rs1800544 comes from drug-induced weight gain. Sickert et al. 2009⁴⁴ Sickert et al. 2009
Sickert L et al. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics, 2009 tracked 60 European-Americans on clozapine or olanzapine for 6–14 weeks. C allele carriers (CC + CG) gained 3.73 ± 4.13 kg, compared with just 0.23 ± 2.92 kg for GG homozygotes (p=0.013). The same directionality appeared with the antidepressant mirtazapine: Lee et al. 2009⁵⁵ Lee et al. 2009
Lee HY et al. Association of the adrenergic alpha 2a receptor -1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Research, 2009 found the CC genotype gained more weight after 8 weeks of mirtazapine treatment in 314 MDD patients (p=0.052).

Conversely, when patients were switched from weight-inducing antipsychotics to metabolically neutral alternatives, the GG genotype showed the greatest benefit: Roffeei et al. 2014⁶⁶ Roffeei et al. 2014
Roffeei SN et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Human Psychopharmacology, 2014 found GG carriers lost 1.04 ± 1.63 kg/m² BMI vs only 0.32 ± 1.41 kg/m² for C allele carriers when switching to aripiprazole or ziprasidone (p=0.013).

On metabolic physiology, Rosmond et al. 2002⁷⁷ Rosmond et al. 2002
Rosmond R et al. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. Journal of Internal Medicine, 2002 studied 284 Swedish men and found that heterozygous C/G carriers had impaired dexamethasone suppression (higher post-dex cortisol, p=0.009) and elevated fasting glucose compared with GG homozygotes (p=0.017). The mechanism proposed: altered receptor density destabilises sympathetic–hypothalamic–pituitary–adrenal axis tone, raising ambient cortisol and blunting insulin sensitivity. Separately, Kochetova et al. 2015⁸⁸ Kochetova et al. 2015
Kochetova OV et al. Genetic association of ADRA2A and ADRB3 genes with metabolic syndrome among the Tatars. Genetika, 2015 found GG and GC genotypes were associated with higher fasting insulin and elevated HOMA-IR in Tatar women with metabolic syndrome — a finding that conflicts somewhat with the antipsychotic weight-gain literature and illustrates that the direction of effect likely depends on the specific metabolic context and concomitant treatments.

Practical Actions

The most actionable signal from rs1800544 relates to medications that engage the adrenergic system or carry known weight-gain liabilities. C allele carriers starting clozapine, olanzapine, or mirtazapine face substantially elevated risk of rapid weight accumulation. Pre-emptive monitoring of weight and waist circumference, and selecting metabolically neutral alternatives where clinically appropriate, represents the most evidence-grounded response.

Separately, the G allele is associated with better methylphenidate response in ADHD (Hain et al. 2022⁹⁹ Hain et al. 2022
Hain DT et al. Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in ADHD. Biological Psychiatry Global Open Science, 2022; OR 3.08, 95% CI 1.71–5.56, p=0.0002 across 9 studies). This is a pharmacogenomic signal with potential utility in paediatric ADHD prescribing decisions.

Interactions

The ADRA2A rs553668 and rs521674 promoter variants tag partially overlapping haplotypes within the same regulatory region, and their combined effects on receptor expression may be additive. The 5-fold expression range reported by Small et al. encompasses multi-SNP haplotypes, not single variants in isolation; users carrying multiple ADRA2A promoter variants may have amplified effects on adrenergic tone.

In the context of obesity genetics, ADRA2A interacts functionally with the beta-3 adrenergic receptor (ADRB3, rs4994) — both regulate sympathetic control of adipose tissue lipolysis from opposing directions. Combined carriership of ADRA2A and ADRB3 risk variants has been explored in metabolic syndrome cohorts.

Every milligram of zinc you absorb from food passes through a single gateway in the intestinal wall: a protein called ZIP4¹¹ ZIP4
Zinc-Iron transporter Protein 4, encoded by SLC39A4 on chromosome 8q24.3; expressed at the apical membrane of duodenal and jejunal enterocytes; the sole high-capacity zinc importer in the mammalian gut. When ZIP4 stops working entirely — through rare pathogenic mutations — the result is acrodermatitis enteropathica, a severe inherited zinc deficiency disease. But rs1871534 is not one of those rare mutations. It is one of the most common SNPs in the human genome, and its story is one of the most striking examples of recent positive selection in human evolution.

The rs1871534 variant swaps a leucine for a valine at position 372 of the ZIP4 protein (Leu372Val). The valine form — the C allele on the plus strand — is carried by essentially every person of West African descent and by virtually nobody of European or East Asian ancestry. The [FST | a measure of population differentiation ranging from 0 (identical frequency) to 1 (completely different); values above 0.90 are extremely rare for common SNPs] between Europeans and Yorubans (West Africans) for this variant is 0.99999977 — the most differentiated common SNP in the genome at the time of its discovery.

The Mechanism

Engelken et al. (2014)²² Engelken et al. (2014) investigated why this SNP shows such extreme population differentiation. They expressed both the Leu372 and Val372 forms of ZIP4 in HeLa cells and measured three outcomes: protein levels at the cell surface, baseline intracellular zinc, and zinc uptake rate. Val372 (the West African form) showed significantly reduced surface expression, lower basal intracellular zinc, and reduced zinc uptake compared to Leu372. The variant does not eliminate ZIP4 function — it reduces its efficiency.

ZIP4 is regulated through zinc-dependent endocytosis: when zinc is abundant, ZIP4 is pulled off the cell surface and degraded; when zinc is scarce, ZIP4 is rapidly trafficked back to the apical membrane to capture more zinc. The Leu372Val substitution sits in a transmembrane domain of the protein and appears to alter the protein's stability at the cell surface — [effectively reducing the maximum capacity of the intestinal zinc absorption system | Wang et al. 2004 showed that reduced surface expression is the primary mechanism by which ZIP4 missense variants impair transport (PMID 14709598)].

The Evidence

The key study is the 2014 analysis by Engelken and colleagues³³ Engelken and colleagues
Engelken J et al. Extreme population differences in the human zinc transporter ZIP4 (SLC39A4) are explained by positive selection in Sub-Saharan Africa. PLoS Genet, 2014. Using coalescent simulations that accounted for local recombination hotspots, they demonstrated that the extreme allele frequency differences cannot be explained by genetic drift alone — directional selection favoring the Val372 allele in sub-Saharan Africa with a selection coefficient of approximately 0.5% is the most parsimonious explanation. This is a modest but sustained selective advantage, consistent with the allele rising to near-fixation over thousands of generations.

Why would reduced zinc absorption be advantageous? Zinc is essential for many bacterial and parasitic pathogens. The human immune system uses zinc-starvation as a front-line antimicrobial weapon — macrophages deliberately flood zinc into vesicles containing intracellular bacteria to kill them. The authors hypothesize that reduced intestinal zinc uptake by Val372-ZIP4 may also reduce systemic zinc availability to pathogens, conferring a survival advantage in high-pathogen-burden environments like sub-Saharan Africa. This hypothesis remains speculative — no direct in vivo evidence in humans has yet tested it — but it is consistent with the geographic distribution of selection and with what is known about nutritional immunity.

The functional consequence for the individual: Val372/Val372 (CC) homozygotes absorb zinc less efficiently than Leu372/Leu372 (GG) carriers. At typical dietary zinc intakes this may not produce frank deficiency, but it creates a narrower margin — particularly on high-phytate diets that already impair zinc bioavailability.

Practical Actions

For CC carriers (almost exclusively of West African or recent African ancestry), the gap between dietary zinc intake and actual absorption is wider than for GG carriers. Phytate-rich staple diets — common in sub-Saharan Africa — compound this by further reducing bioavailability. The most direct interventions are dietary: prioritise animal-source zinc (which bypasses phytate inhibition) and reduce phytate intake through food preparation techniques. Monitoring serum zinc provides an objective check on zinc adequacy.

For CG heterozygotes, a modest intermediate effect on ZIP4 surface expression is expected; the practical relevance is smaller but the same dietary principles apply.

Interactions

With SLC30A1 (ZnT1, rs3738198): ZIP4 handles zinc import at the apical membrane; ZnT1 handles export at the basolateral membrane. Individuals carrying reduced-function alleles at both transporters face a double constraint on net zinc delivery to the portal circulation.

With dietary phytate: The gene-diet interaction is the dominant modifiable factor. Phytate in legumes, wholegrains, and maize-based staples forms insoluble zinc-phytate complexes in the gut, reducing absorption to 10–15% vs 25–40% for animal-source zinc. For CC carriers, this interaction is clinically meaningful — phytate in the context of reduced ZIP4 capacity compounds into significant functional zinc inadequacy.

With pathogenic SLC39A4 variants: Compound heterozygosity — one Leu372Val allele plus one pathogenic acrodermatitis enteropathica allele on the other chromosome — has not been systematically studied but is theoretically possible. Because the pathogenic variants (p.Arg95Cys, p.Gln278His, etc.) cause null or near-null ZIP4 function, the Leu372Val allele would provide residual function on that chromosome.

The HPS3 gene encodes a subunit of the BLOC-2 complex¹¹ BLOC-2 complex
Biogenesis of Lysosome-related Organelles Complex 2, a multi-protein machine that organizes the intracellular trafficking of cargo into specialized organelles — including platelet dense granules (which store ADP and serotonin needed for blood clotting) and melanosomes (which produce and distribute skin and eye pigment). The rs201227603 variant disrupts a splice donor site at the start of intron 5, causing the cell's RNA-splicing machinery to skip exon 5 entirely and produce a non-functional protein. In people who inherit two copies, this causes Hermansky-Pudlak syndrome type 3 (HPS3)²² Hermansky-Pudlak syndrome type 3 (HPS3), a rare autosomal recessive disorder. In people who carry one copy, there are no symptoms — but the variant can be passed to children.

The Mechanism

rs201227603 lies at position chr3:149,145,547 (GRCh38) within the HPS3 gene on the plus strand. The G→A change at the +1 position of intron 5 destroys the canonical GT splice donor sequence³³ GT splice donor sequence
The GT dinucleotide at the start of almost every intron is essential for the spliceosome to recognize and excise the intron, causing exon 5 skipping and a frameshift that eliminates BLOC-2 function. Without functional BLOC-2, melanosomes fail to mature properly (causing oculocutaneous albinism) and platelet dense granules fail to form (causing a delta storage pool deficiency⁴⁴ delta storage pool deficiency
Platelets normally store ADP, ATP, and serotonin in dense granules; without them, the secondary wave of platelet aggregation fails, prolonging bleeding time). Critically, HPS3 does not affect the BLOC-3 or AP-3 complexes that are responsible for pulmonary fibrosis in HPS types 1, 2, and 4. HPS3 is among the milder HPS subtypes: hypopigmentation can be subtle enough to be missed, and pulmonary fibrosis is not a feature.

The Evidence

Huizing et al. (2001)⁵⁵ Huizing et al. (2001) first characterized the 1303+1G→A mutation (now rs201227603 in dbSNP) as a founder variant in Ashkenazi Jews, identifying five of eight non-Puerto Rican HPS3 patients as being of Ashkenazi descent and finding a carrier frequency of approximately 1 in 235 (0.43%) in anonymous Ashkenazi Jewish samples. Current gnomAD v4 exome data confirms the striking population stratification: the variant reaches an allele frequency of ~0.172% in Ashkenazi Jews, versus <0.001% in all other populations. Two copies would cause full HPS3 disease; in the Ashkenazi Jewish community, the expected disease frequency is approximately 1 in 33,000 births.

Huizing et al. (2020)⁶⁶ Huizing et al. (2020) comprehensively reviewed all 264 variants across 10 HPS genes and confirmed that pulmonary fibrosis is restricted to BLOC-3 (HPS1, HPS4) and AP-3 (HPS2) deficiencies — not to HPS3 (BLOC-2 deficiency) — making prognosis for HPS3 significantly better than for the most severe subtypes.

Marek-Yagel et al. (2022)⁷⁷ Marek-Yagel et al. (2022) described six compound heterozygous HPS3 patients carrying a splice site variant (c.1163+1G>A) and a large deletion; all presented with variable oculocutaneous albinism and ecchymoses, but none had pulmonary involvement, consistent with the mild BLOC-2 phenotype.

Practical Actions

For carriers (one copy): no health effects expected, but genetic counseling is valuable, particularly for Ashkenazi Jewish individuals planning families. If both partners carry the variant, each pregnancy has a 25% chance of producing an affected child.

For homozygous individuals (two copies, causing HPS3 disease): management centers on eye protection (albinism increases UV sensitivity and reduces visual acuity), bleeding precautions (dense granule deficiency prolongs bleeding time), and monitoring skin for UV-induced damage. Desmopressin (DDAVP) can correct the prolonged bleeding time prior to procedures. NSAIDs and aspirin must be strictly avoided, as they further impair platelet function.

Interactions

HPS3 disease requires biallelic loss-of-function in the HPS3 gene. Compound heterozygosity (one splice donor variant + one deletion or other loss-of-function allele) produces the same clinical picture as homozygosity. No published compound action is documented between rs201227603 and variants in other HPS genes, though digenic combinations are theoretically possible in pathway biology.

Fibrinogen is the blood's primary scaffolding protein — the raw material that thrombin converts into fibrin, the structural backbone of every blood clot. But fibrinogen is not a single molecule. The liver produces two principal isoforms that differ at their gamma chain tip: fibrinogen gamma-A¹¹ fibrinogen gamma-A
The predominant isoform (~85-90% of total fibrinogen) with standard interactions with thrombin, platelets, and Factor XIII and fibrinogen gamma-prime²² fibrinogen gamma-prime
A minority isoform (~10-15% of total) with an extended gamma chain that uniquely binds thrombin, Factor XIII, and has distinct platelet interactions. The rs2066865 variant determines how much gamma-prime your liver makes relative to gamma-A — and that ratio turns out to matter for your thrombosis risk.

The Mechanism

The FGG gene on chromosome 4 encodes the fibrinogen gamma chain. Two alternative polyadenylation sites in its 3' downstream region³³ 3' downstream region
The non-coding region after the gene's stop codon that controls mRNA processing and determines which protein isoform is produced create two mRNA transcripts: a shorter one producing the standard gamma-A chain and a longer one producing the extended gamma-prime chain. The rs2066865 variant (10034C>T on the coding strand; G>A on the plus strand) sits in this alternative splicing control region and shifts the balance toward the shorter transcript — meaning carriers of the A allele produce proportionally less fibrinogen gamma-prime and more gamma-A.

Fibrinogen gamma-prime has several unique properties that modulate clot risk. It binds thrombin with high affinity through exosite II, effectively sequestering thrombin and limiting its availability for further coagulation. It also alters clot architecture⁴⁴ clot architecture
Fibrinogen gamma-prime produces clots with a looser, more porous structure that is more easily dissolved by fibrinolysis — the body's clot-clearing system. When gamma-prime levels fall (as in A-allele carriers), clots form more readily and are more resistant to fibrinolysis — a procoagulant shift by two independent mechanisms simultaneously.

The Evidence

The original landmark study by Uitte de Willige et al.⁵⁵ Uitte de Willige et al.
Published in Blood 2005, the first paper to identify rs2066865 as an independent DVT risk factor identified this variant as an independent deep venous thrombosis risk factor through the gamma-prime fibrinogen mechanism. The largest genetic confirmation came from a UK Biobank and Veterans Affairs genome-wide study by Klarin et al.⁶⁶ UK Biobank and Veterans Affairs genome-wide study by Klarin et al.
816,694 participants; p-value 10⁻⁸⁸ for VTE association; OR 1.22 per A allele — one of the strongest genetic signals in the VTE literature with over 800,000 participants, establishing an odds ratio of approximately 1.22 per A allele at genome-wide significance (p = 10⁻⁸⁸).

In a prospective population-based study from Norway⁷⁷ prospective population-based study from Norway
640 VTE cases among 3,734 age-weighted participants in the Tromsø cohort, homozygous AA carriers showed a hazard ratio of 1.7 (95% CI 1.2–2.3) for VTE. When active cancer was present, the risk compounded further to HR 2.0 — synergy between genetic and acquired thrombotic risk.

A large Czech study of 2,630 VTE patients versus 2,637 controls⁸⁸ 2,630 VTE patients versus 2,637 controls
Kvasnicka et al. 2025, Clinical and Applied Thrombosis/Hemostasis confirmed a dose-response relationship: heterozygous GA carriers had 1.37-fold increased VTE risk and homozygous AA carriers had 1.77-fold increased risk. A separate microvascular surgery cohort found microvascular thrombosis rates of 7.6% (GG), 22.7% (GA), and 33% (AA)⁹⁹ microvascular thrombosis rates of 7.6% (GG), 22.7% (GA), and 33% (AA)
Drizlionoka et al. 2019; 104 patients undergoing microvascular flap surgery, with plasma fibrinogen concentrations also rising with each A allele.

The association extends beyond venous thrombosis. In Han Chinese participants¹⁰¹⁰ Han Chinese participants
Discovery and replication cohorts totaling 1,268 PE cases and 17,663 controls, rs2066865 reached genome-wide significance for pulmonary embolism (p = 3.81 × 10⁻¹⁴, OR 1.37). In systemic lupus erythematosus patients, the variant showed OR 1.91 for venous thrombosis in white participants and OR 2.19 for arterial thrombosis in Hispanic Americans — suggesting that the procoagulant phenotype interacts with the inflammatory milieu of autoimmune disease.

Practical Implications

The per-allele OR of ~1.22 translates to a moderate absolute risk increase. Unlike the rare, high-penetrance thrombophilias (Factor V Leiden homozygosity, antithrombin deficiency), rs2066865 is common enough — about 7% of people carry two A alleles — that it contributes meaningfully to population-attributable VTE burden. The effect is additive: each additional A allele incrementally shifts the gamma/gamma-prime ratio and modestly elevates risk.

For carriers, awareness is most actionable before high-risk periods: surgery, prolonged immobilization, long-haul travel, hormonal changes (pregnancy, oral contraceptive initiation), and during cancer treatment. The variant also modifies fibrinogen levels measurably — AA homozygotes in the Drizlionoka cohort had nearly double the plasma fibrinogen of GG homozygotes — which is itself an established cardiovascular risk factor.

Interactions

The most clinically important interactions are with other inherited thrombophilias. Carriers of both rs2066865 A allele(s) and Factor V Leiden (rs6025)¹¹¹¹ Factor V Leiden (rs6025)
F5 R506Q, the most common inherited thrombophilia at 5% carrier frequency in Europeans; creates resistance to activated protein C, a natural anticoagulant or prothrombin G20210A (rs1799963)¹²¹² prothrombin G20210A (rs1799963)
F2 3'UTR variant that elevates prothrombin production by 30%; the second most common inherited thrombophilia face a compounded risk from independent pro-coagulant mechanisms acting simultaneously. Similarly, Factor XI rs2289252¹³¹³ Factor XI rs2289252
F11 intronic variant associated with elevated Factor XI levels and modestly elevated VTE risk is included in clinical thrombophilia panels alongside rs2066865. Acquired thrombophilic states — cancer, antiphospholipid syndrome, pregnancy — add independently to the genetic baseline.